BRIEF published on 06/06/2024 at 13:05, 2 years 2 months ago Theralase détruit avec succès le cancer du poumon Technologies Théralase Cancer Du Poumon Rutherrin® Étude Préclinique
PRESS RELEASE published on 06/06/2024 at 13:00, 2 years 2 months ago Theralase(R) Successfully Destroys Lung Cancer Theralase® Technologies Inc. announces preclinical success with Rutherrin® compound in targeting Non-Small Cell Lung Cancer. Results show improved tumour destruction and slower progression Theralase Technologies Inc. Cancer Treatment Preclinical Study NSCLC Rutherrin Compound
BRIEF published on 06/04/2024 at 13:05, 2 years 2 months ago Theralase® Technology Effective in Virus Inactivation Theralase Ruvidar Antiviral Research Virus Inactivation Heliyon
BRIEF published on 06/04/2024 at 13:05, 2 years 2 months ago Technologie Theralase® efficace pour l'inactivation des virus Theralase Ruvidar Recherche Antivirale Heliyon Inactivation Des Virus
PRESS RELEASE published on 06/04/2024 at 13:00, 2 years 2 months ago Theralase(R) Technology Effective in Virus Inactivation Theralase Technologies Inc. announces successful inactivation of various viruses with lead compound RuvidarTM through peer-reviewed research. Potential for viral vaccine development highlighted Theralase Technologies Inc. RuvidarTM Peer-Reviewed Research Viral Inactivation Viral Vaccine Development
BRIEF published on 05/30/2024 at 13:05, 2 years 2 months ago Theralase Releases 1Q2024 Financial Statements Financial Results Cancer Treatment Theralase Study II PDCs
BRIEF published on 05/30/2024 at 13:05, 2 years 2 months ago Theralase publie ses états financiers du 1T2024 Résultats Financiers Traitement Du Cancer Theralase Étude II PDC
PRESS RELEASE published on 05/30/2024 at 13:00, 2 years 2 months ago Theralase(R) Release's 1Q2024 Financial Statements Theralase® releases unaudited interim consolidated 1Q2024 financial statements. Company to host conference call on June 6th, 2024. Study II update and Break Through Designation progress discussed Conference Call Financial Statements Break Through Designation Theralase Study II
BRIEF published on 04/24/2024 at 13:05, 2 years 3 months ago Theralase Technologies Inc. Completes $750,200 Funding Round Private Placement Pharmaceuticals Clinical Research Investment Theralase Technologies
BRIEF published on 04/24/2024 at 13:05, 2 years 3 months ago Theralase Technologies Inc. finalise une ronde de financement de 750 200 $ Investissement Placement Privé Médicaments Recherche Clinique Technologies Théralase
Published on 08/14/2026 at 16:55, 1 hour 20 minutes ago SLAM Reports 1.19% Copper Equivalent Over 24.6 Metres in Hole GW26-29 From the Goodwin Copper-Nickel-Cobalt Project
Published on 08/14/2026 at 13:30, 4 hours 45 minutes ago Digi Power X Reports Second Quarter 2026 Financial Results and Provides Operational Update and 2027 Outlook
Published on 08/14/2026 at 13:15, 5 hours ago Mako Mining Reports Q2 2026 Financial Results, Including Adjusted EBITDA(1) of US$31.7 Million and EPS of US$0.16/Share
Published on 08/14/2026 at 13:10, 5 hours 5 minutes ago SouthGobi Announces Second Quarter 2026 Unaudited Financial and Operating Results
Published on 08/14/2026 at 09:01, 9 hours 14 minutes ago Apex Announces Filing of Final Base Shelf Prospectus
Published on 08/14/2026 at 16:05, 2 hours 10 minutes ago GATORADE WELCOMES AITANA BONMATÍ TO TEAM GATORADE AHEAD OF THE NEW FOOTBALL SEASON
Published on 08/14/2026 at 15:02, 3 hours 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/14/2026 at 15:02, 3 hours 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 08/14/2026 at 15:01, 3 hours 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 08/11/2026 at 17:45, 3 days ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 3 days ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 4 days ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 4 days ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
